NeuClone and Serum Institute collaborate on biosimilars

08-07-2014

Australian biotechnology company NeuClone has signed an agreement with vaccine maker the Serum Institute of India to manufacture and supply ten biosimilar monoclonal antibody drugs around the world.


NeuClone, Serum Institute of India, co-development programme, biosimilars

LSIPR